CARY, N.C., Nov. 13 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. , a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has appointed Andrew K. W. Powell, Esq. Executive Vice President, General Counsel and Secretary. In this role, Mr. Powell will join the Company’s executive management team and manage its legal function and corporate governance processes. He will report to Craig Collard, Cornerstone’s President and Chief Executive Officer.
“Andrew has an outstanding track record in senior level corporate legal positions, and we are pleased to welcome him to Cornerstone,” said Mr. Collard. “A key component of our growth strategy is acquiring products to build our product portfolio, and we expect Andrew’s significant transaction experience to be an invaluable asset to us as we continue to expand our business.”
About Cornerstone Therapeutics
Safe Harbor Statement
CONTACT: for Investor Relations, Evan Smith, evan.smith@fd.com or Brian
Ritchie, brian.ritchie@fd.com, both of FD, +1-212-850-5600; or for Media
Relations, Robert Stanislaro of FD, +1-212-850-5600,
robert.stanislaro@fd.com
